Every item on the wire - press releases, filings, ratings, everything. https://quantisnow.com/news/all-insights en-us Mon, 08 Jun 2026 06:53:24 GMT Creates a scaled global provider of specialty ingredient solutions for a healthier, tastier and more sustainable future of food Broadens Ingredion's specialty ingredients platform across texturants, sugar reduction, and fortification, adding complementary capabilities in multi-ingredient systems and recipe developmentExpands Ingredion's ability to address customer needs across a wider range of end use categories and applicationsBrings together complementary geographic supply networks across the Americas, Europe, the Middle East and Africa, and Asia Pacific to deliver faster, more reliable and cost-effective ingredients and solutions for customers and consumers worldwide WESTCHESTER, Ill., https://quantisnow.com/insight/ingredion-announces-recommended-all-cash-acquisition-of-tate-lyle-6592331 https://quantisnow.com/insight/ingredion-announces-recommended-all-cash-acquisition-of-tate-lyle-6592331 Mon, 08 Jun 2026 06:20:58 GMT Purchase of own shares LONDON, UK / ACCESS Newswire / June 8, 2026 / InterContinental Hotels Group PLC (the "Company"), The Company announces that on 05 June 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.Date of purchase:05 June 2026Aggregate number of ordinary shares purchased:10,000Lowest price paid per share:$ 160.9500Highest https://quantisnow.com/insight/intercontinental-hotels-group-plc-announces-transaction-in-own-shares---6592330 https://quantisnow.com/insight/intercontinental-hotels-group-plc-announces-transaction-in-own-shares---6592330 Mon, 08 Jun 2026 06:00:00 GMT Approximately £1.7 billion committed to capacity buildout at four sites Growing commercial and AI R&D presence at London hub UK customers using Nebius include pioneers in financial services, healthcare and life sciences Nebius (NASDAQ:NBIS), the AI cloud company, today announced it is investing approximately £1.7 billion to build out capacity in the UK with three new deployments of NVIDIA infrastructure, as the company continues to expand its commercial and AI R&D hub in London. Nebius launched its first UK deployment of NVIDIA Blackwell Ultra infrastructure in November 2025. The three new sites will also deploy the latest generations of NVIDIA's full-stack, end-to-end AI factor https://quantisnow.com/insight/nebius-expands-in-uk-with-more-nvidia-powered-infrastructure-more-customers-6592329 https://quantisnow.com/insight/nebius-expands-in-uk-with-more-nvidia-powered-infrastructure-more-customers-6592329 Mon, 08 Jun 2026 06:00:00 GMT RIYADH, Saudi Arabia, June 08, 2026 (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ:RXT), a global enterprise AI infrastructure and solutions provider, today announced the establishment of its regional headquarters in Riyadh, Saudi Arabia, reinforcing the company's long-term commitment to the Kingdom of Saudi Arabia and the broader Middle East region. The new regional headquarters will serve as a strategic hub for Rackspace Technology's operations and customer engagement efforts, supporting organizations across enterprise, government, and regulated industries as they accelerate digital transformation initiatives aligned with Saudi Arabia's Vision 2030 agenda. The Riyadh office will be https://quantisnow.com/insight/rackspace-technology-establishes-regional-headquarters-in-riyadh-to-accelerate-cloud-6592328 https://quantisnow.com/insight/rackspace-technology-establishes-regional-headquarters-in-riyadh-to-accelerate-cloud-6592328 Mon, 08 Jun 2026 05:30:00 GMT WISeKey, The Hashgraph Group and Hedera Launch QAIT Q-Day Security Assessment Platform on the SEALCOIN Quantum Marketplace First Quantum Security Service to Launch Within SEALCOIN's Dedicated Quantum Marketplace, Enabling Organizations to Assess and Prepare for Quantum-Era Cybersecurity Risks Geneva, Switzerland – June 8, 2026 — WISeKey International Holding Ltd ((SIX: WIHN, NASDAQ:WKEY), a global leader in cybersecurity, digital identity and IoT, today announced the launch of a dedicated Quantum Marketplace within the SEALCOIN platform and the introduction of its flagship application, the QAIT Q-Day Security Assessment Platform. Developed in collaboration with The Hashgraph Group (THG) https://quantisnow.com/insight/wisekey-the-hashgraph-group-and-hedera-launch-qait-q-day-security-6592327 https://quantisnow.com/insight/wisekey-the-hashgraph-group-and-hedera-launch-qait-q-day-security-6592327 Mon, 08 Jun 2026 05:00:00 GMT Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of https://quantisnow.com/insight/roche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-6592326 https://quantisnow.com/insight/roche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-6592326 Mon, 08 Jun 2026 05:00:00 GMT Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milesto https://quantisnow.com/insight/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-6592325 https://quantisnow.com/insight/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-6592325 Mon, 08 Jun 2026 05:00:00 GMT (From left to right) En. Wan Murdani, Senior Vice President, Malaysia Digital Economy Corporation (MDEC); Ms. Zuaida Abdullah, Deputy Chief Executive Officer, Investment Development, Malaysian Investment Development Authority (MIDA); YB Gobind Singh Deo, Minister of Digital; Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty; Billy Lee, Chairman, CSF Advisers Sdn Bhd and Advisor for Malaysia, Digital Realty; and Govind Choudhary, General Manager, Southeast Asia and India, Digital Realty, at the inauguration of Digital Realty's Malaysia operations in Cyberjaya.  KUALA LUMPUR, Malaysia, June 08, 2026 (GLOBE NEWSWIRE) -- Digital Realty (NYSE:DLR), the world's largest cl https://quantisnow.com/insight/digital-realty-launches-malaysia-operations-to-advance-southeast-asias-digital-6592324 https://quantisnow.com/insight/digital-realty-launches-malaysia-operations-to-advance-southeast-asias-digital-6592324 Mon, 08 Jun 2026 04:46:56 GMT Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI agent deploymentOrganizations that design control into their AI systems achieve significantly stronger performance outcomes.ARMONK, N.Y., June 8, 2026 /CNW/ -- A new IBM (NYSE:IBM) Institute for Business Value study reveals that as AI moves from experimentation to enterprise-wide deployment, two-thirds of surveyed CIOs and CTOs report being held accountable for AI systems they do not fully control, while governance struggles to keep pace at scale. The global study* of 2 https://quantisnow.com/insight/new-ibm-study-finds-cios-and-ctos-face-growing-ai-6592323 https://quantisnow.com/insight/new-ibm-study-finds-cios-and-ctos-face-growing-ai-6592323 Mon, 08 Jun 2026 04:01:00 GMT Rumble Has Successfully Secured the Support of 85% of Northern Data's Share Capital In Total, 46% of Northern Data Shares not subject to Transaction Support Agreements Have Been Tendered Additional Acceptance Period Expired on June 1, 2026 – Exchange Offer No Longer Open for Acceptance Closing Expected in mid-June 2026, with application for Delisting of Northern Data Shares expected to be filed immediately Afterwards Transaction Follows Compelling Strategic Rationale Longboat Key, FL, June 08, 2026 (GLOBE NEWSWIRE) -- Rumble Inc. (NASDAQ:RUM) ("Rumble"), the Freedom-First technology platform, today announced the final results for its exchange offer to acquire all outstanding shares o https://quantisnow.com/insight/rumble-announces-final-results-of-exchange-offer-for-northern-data-6592322 https://quantisnow.com/insight/rumble-announces-final-results-of-exchange-offer-for-northern-data-6592322 Mon, 08 Jun 2026 04:01:00 GMT BitGo MENA FZE ("BitGo MENA"), a subsidiary of BitGo Holdings, Inc. (NYSE:BTGO) ("BitGo"), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA's established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA's Broker-Dealer license from Dubai's Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA's regulated product suite under VARA's oversight, marking another step in the region's continued buildout of institutional d https://quantisnow.com/insight/bitgo-mena-launches-regulated-electronic-trading-delivering-full-suite-trading-6592321 https://quantisnow.com/insight/bitgo-mena-launches-regulated-electronic-trading-delivering-full-suite-trading-6592321 Mon, 08 Jun 2026 04:00:00 GMT Proceeds fully fund the company through 2028 and will be used to accelerate commercialization of Solidion's patented Extreme-Climate Battery Technology targeting the Lunar economy and space applications DALLAS, TX, June 07, 2026 (GLOBE NEWSWIRE) -- Solidion Technology Inc. ("Solidion" or the "Company") (NASDAQ:STI), an advanced battery technology solutions provider, today announced that it has entered into a securities purchase agreement with a new institutional investor for the purchase and sale of 2,333,000 shares of common stock (or common stock equivalents) in a private placement priced above market under Nasdaq rules. The offering is expected to result in gross proceeds of $35 milli https://quantisnow.com/insight/solidion-technology-announces-35-million-private-placement-of-common-stock-6592320 https://quantisnow.com/insight/solidion-technology-announces-35-million-private-placement-of-common-stock-6592320 Mon, 08 Jun 2026 01:49:11 GMT FF will hold its FF EAI Robotics Education Ecosystem Strategy, Product Line & New EAI Device Launch at its Los Angeles headquarters on June 16, where the Company will give a full and in-depth introduction to FF's robotics education ecosystem strategy and also launch its EAI education product line and several major new EAI devices. On June 22, at Automate in Chicago, the largest robotics show in North America, FF will hold the FF EAI Robotics Multi-Form Lineup Debut & New Product Launch. FF will use this event to share more on its Three-in-One EAI ecosystem and EAI device lineup. Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) ("Faraday Future", "FF" or the "Company"), a Califo https://quantisnow.com/insight/faraday-future-founder-and-global-ceo-yt-jia-shares-weekly-6592319 https://quantisnow.com/insight/faraday-future-founder-and-global-ceo-yt-jia-shares-weekly-6592319 Sun, 07 Jun 2026 23:30:00 GMT SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company")), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that Everest Medicines (HKEX1952, or "Everest"), has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals ("CORXEL") to acquire the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest Medicines is a biopharmaceutical company focused on discovering, developing https://quantisnow.com/insight/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-6592318 https://quantisnow.com/insight/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-6592318 Sun, 07 Jun 2026 23:30:00 GMT Ramat Gan, Israel, June 07, 2026 (GLOBE NEWSWIRE) -- Odysight.ai® (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company's financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company's discretion to support busines https://quantisnow.com/insight/odysightai-establishes-at-the-market-atm-program-of-up-to-20-million-6592317 https://quantisnow.com/insight/odysightai-establishes-at-the-market-atm-program-of-up-to-20-million-6592317 Sun, 07 Jun 2026 23:15:00 GMT News Summary: SK Telecom plans to build a gigawatt-scale AI Cloud in Korea using the NVIDIA DSX platform, with the first AI factory planned to come online in 2027.The AI Cloud will support sovereign, physical and agentic AI services for enterprises and industries across Korea, building on SK Telecom's network, data center and enterprise infrastructure expertise.NVIDIA DSX will serve as the AI factory architecture blueprint, combining NVIDIA accelerated computing, systems, software and partner technologies to improve time to production and token performance per megawatt.NVIDIA and SK Group are planning to expand their collaboration from AI infrastructure deployments to joint research on next https://quantisnow.com/insight/sk-telecom-and-nvidia-build-ai-infrastructure-to-power-koreas-6592316 https://quantisnow.com/insight/sk-telecom-and-nvidia-build-ai-infrastructure-to-power-koreas-6592316 Sun, 07 Jun 2026 23:00:00 GMT News Summary: NAVER, an AI Cloud, will build AI factories on the NVIDIA DSX platform at gigawatt scale, starting with AI infrastructure expansion at GAK Sejong.NVIDIA DSX gives NAVER a proven AI factory blueprint to serve Korea's industries and global AI cloud customers as demand for useful AI surges at lowest token cost.NAVER will use NVIDIA full-stack AI platforms, models and software to advance regional AI models including next-generation HyperCLOVA X models, its Seoul World Model development and agentic AI services. SEOUL, South Korea, June 07, 2026 (GLOBE NEWSWIRE) -- NVIDIA and NAVER today announced that NAVER will expand sovereign AI infrastructure, starting at 55 megawatts with p https://quantisnow.com/insight/naver-expands-ai-infrastructure-with-nvidia-to-serve-surging-global-6592315 https://quantisnow.com/insight/naver-expands-ai-infrastructure-with-nvidia-to-serve-surging-global-6592315 Sun, 07 Jun 2026 23:00:00 GMT News Summary: NVIDIA and SK hynix announce multiyear technology partnership for next-generation memory aligned to NVIDIA's AI infrastructure roadmap.The agreement supports supply for advanced memory, addressing the extended development cycles, advanced fabrication and capital investments to sustain the global buildout of AI factories.SK hynix will diversify into new markets NVIDIA is creating — across AI infrastructure, personal AI and physical AI — codeveloping memory for NVIDIA Vera Rubin AI supercomputers, Vera CPUs, RTX Spark-powered PCs and Jetson Thor robotic computing platforms.The two companies will apply AI to semiconductor chip design and manufacturing, using NVIDIA CUDA-X librari https://quantisnow.com/insight/nvidia-and-sk-hynix-announce-multiyear-technology-partnership-to-advance-6592314 https://quantisnow.com/insight/nvidia-and-sk-hynix-announce-multiyear-technology-partnership-to-advance-6592314 Sun, 07 Jun 2026 23:00:00 GMT $4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. T https://quantisnow.com/insight/volitionrx-announces-pricing-of-46-million-public-offering-6592313 https://quantisnow.com/insight/volitionrx-announces-pricing-of-46-million-public-offering-6592313 Sun, 07 Jun 2026 22:30:00 GMT VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes CareTHOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.The data include new Phase 3 VESALIUS-CV subgroup results for Repatha® in patients with high-risk diabetes (microvascular disease, insulin use or diabetic duration ≥10 years) and e https://quantisnow.com/insight/amgen-presents-new-data-across-its-cardiometabolic-portfolio-at-american-6592312 https://quantisnow.com/insight/amgen-presents-new-data-across-its-cardiometabolic-portfolio-at-american-6592312 Sun, 07 Jun 2026 20:45:00 GMT Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests. Plans to continue operations without interruption and it is business-as-usual for the Company in providing service for existing Medicare consumers and partners. CHICAGO, June 07, 2026 (GLOBE NEWSWIRE) -- GoHealth, Inc. ("GoHealth" or the "Company"), a health insurance marketplace and Medicare-focused digital health company, announced that GoHealth and certain of its subsidiaries have voluntarily filed chapter 11 petitions (the https://quantisnow.com/insight/gohealth-inc-to-strengthen-its-position-ahead-of-aep-2026-6592311 https://quantisnow.com/insight/gohealth-inc-to-strengthen-its-position-ahead-of-aep-2026-6592311 Sun, 07 Jun 2026 19:40:12 GMT Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 ​ Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with https://quantisnow.com/insight/zealand-pharma-announces-boehringer-ingelheims-survodutide-phase-iii-trial-in-6592310 https://quantisnow.com/insight/zealand-pharma-announces-boehringer-ingelheims-survodutide-phase-iii-trial-in-6592310 Sun, 07 Jun 2026 18:30:00 GMT In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetesAcross studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic riskINDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced signi https://quantisnow.com/insight/lillys-foundayo-orforglipron-the-only-oral-glp-1-taken-without-food-6592309 https://quantisnow.com/insight/lillys-foundayo-orforglipron-the-only-oral-glp-1-taken-without-food-6592309 Sun, 07 Jun 2026 15:00:00 GMT Complete reimagining of the park's family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney Tunes Land media kit available HERE.LOS ANGELES, June 6, 2026 /PRNewswire/ -- Six Flags Magic Mountain is excited to announce that  Looney Tunes™ Land, a uniquely themed area with loveable characters, is now open. The refreshed family-friendly area has been reimagined where the timeless fun of Looney Tunes™ comes to life. Developed in partnership with Warner Bros. Discovery Global Experiences and designed for young adventurers and families alike, Looney Tunes Land brings together colorful environments, pl https://quantisnow.com/insight/looney-tunes-land-now-open-at-six-flags-magic-mountain-6592308 https://quantisnow.com/insight/looney-tunes-land-now-open-at-six-flags-magic-mountain-6592308 Sun, 07 Jun 2026 04:08:00 GMT What's happening: Temperatures are forecast to reach the 90s, pushing cooling systems to run longer and use more energy to maintain indoor temperaturesWhy it matters: Acting now with a few simple steps can help reduce energy use during the heat waveCHARLOTTE, N.C., June 6, 2026 /PRNewswire/ -- High temperatures are forecast across the Carolinas this weekend and next week, and Duke Energy has tips to help you take control of your energy use while keeping you and your family cool. Tips to save energy and money Set your thermostat to the highest comfortable setting. Even a couple of degrees can help save energy and money. Keep in https://quantisnow.com/insight/duke-energy-offers-tips-to-save-energy-and-money-as-6592307 https://quantisnow.com/insight/duke-energy-offers-tips-to-save-energy-and-money-as-6592307 Sat, 06 Jun 2026 23:05:00 GMT Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance  New data expands on findings shared at ATTD and reinforces Eversense 365's strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year GERMANTOWN, Md., June 06, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals https://quantisnow.com/insight/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-6592306 https://quantisnow.com/insight/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-6592306 Sat, 06 Jun 2026 21:00:00 GMT New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically meaningful reductions in body weight, body mass index and waist circumference, with numerically greater benefit in those taking GLP-1 receptor agonists or tirzepatide Late-breaking data from the MOMENTUM trial confirm high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stag https://quantisnow.com/insight/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-6592305 https://quantisnow.com/insight/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-6592305 Sat, 06 Jun 2026 20:45:00 GMT Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1 Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1 DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonst https://quantisnow.com/insight/dexcom-connect-study-the-most-significant-clinical-study-demonstrating-cgm-6592304 https://quantisnow.com/insight/dexcom-connect-study-the-most-significant-clinical-study-demonstrating-cgm-6592304 Sat, 06 Jun 2026 18:45:00 GMT In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesityIn addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%)In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1CINDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), tod https://quantisnow.com/insight/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-6592303 https://quantisnow.com/insight/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-6592303 Sat, 06 Jun 2026 18:30:00 GMT NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (NASDAQ:AIFA) ("AIFA" or the "Company") today provided a strategic update. Following the Company's previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group ("HyalRoute") and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an "AI infrastructure network powered by optical technologies" and an "AI application services matrix." The Company stated that, on June 5, AIFA Ch https://quantisnow.com/insight/all-in-futuretech-alliance-provides-strategic-updates-hainan-aifa-digital-6592302 https://quantisnow.com/insight/all-in-futuretech-alliance-provides-strategic-updates-hainan-aifa-digital-6592302 Sat, 06 Jun 2026 13:52:17 GMT Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in interventionNearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association's (ADA) June 2026 86th Scientific https://quantisnow.com/insight/new-abbott-data-show-many-people-with-diabetes-may-not-6592301 https://quantisnow.com/insight/new-abbott-data-show-many-people-with-diabetes-may-not-6592301 Sat, 06 Jun 2026 13:00:00 GMT Results from multiple Phase 2b dose finding studies for berobenatide (PF'3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy VESPER-1 achieved a non-placebo-adjusted weight loss of almost 16% with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials Pfizer Inc. (NYSE:PFE) today presented detailed results from multiple Phase 2 https://quantisnow.com/insight/robust-phase-2b-efficacy-and-favorable-tolerability-support-monthly-dosing-6592300 https://quantisnow.com/insight/robust-phase-2b-efficacy-and-favorable-tolerability-support-monthly-dosing-6592300 Sat, 06 Jun 2026 13:00:00 GMT STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet's technology today—it also fuels https://quantisnow.com/insight/insulet-reveals-new-data-supporting-breakthrough-omnipod-6-and-fully-6592299 https://quantisnow.com/insight/insulet-reveals-new-data-supporting-breakthrough-omnipod-6-and-fully-6592299 Sat, 06 Jun 2026 11:00:00 GMT Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978  Deep, dose-dependent B cell depletion observed in peripheral blood and tissue Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan's Immunology Day on June 10 CAMBRIDGE, Mass., June 06, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential firs https://quantisnow.com/insight/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-6592298 https://quantisnow.com/insight/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-6592298 Sat, 06 Jun 2026 09:15:00 GMT 4 - WhiteHorse Finance, Inc. (0001552198) (Issuer) https://quantisnow.com/insight/director-bolduc-john-bought-97390-worth-of-shares-14280-units-6592297 https://quantisnow.com/insight/director-bolduc-john-bought-97390-worth-of-shares-14280-units-6592297 Sat, 06 Jun 2026 01:45:45 GMT SCHEDULE 13D/A - GameStop Corp. (0001326380) (Filed by) https://quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-gamestop-corporation-6592296 https://quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-gamestop-corporation-6592296 Sat, 06 Jun 2026 01:38:48 GMT 4 - LENSAR, Inc. (0001320350) (Issuer) https://quantisnow.com/insight/director-hammer-todd-b-was-granted-17421-shares-increasing-direct-6592295 https://quantisnow.com/insight/director-hammer-todd-b-was-granted-17421-shares-increasing-direct-6592295 Sat, 06 Jun 2026 01:34:43 GMT 4 - Delek US Holdings, Inc. (0001694426) (Issuer) https://quantisnow.com/insight/director-sutil-vicky-sold-89808-worth-of-shares-1871-units-6592294 https://quantisnow.com/insight/director-sutil-vicky-sold-89808-worth-of-shares-1871-units-6592294 Sat, 06 Jun 2026 01:34:12 GMT 4 - LENSAR, Inc. (0001320350) (Issuer) https://quantisnow.com/insight/director-ellis-thomas-b-was-granted-17421-shares-increasing-direct-6592293 https://quantisnow.com/insight/director-ellis-thomas-b-was-granted-17421-shares-increasing-direct-6592293 Sat, 06 Jun 2026 01:31:03 GMT 4 - Natera, Inc. (0001604821) (Issuer) https://quantisnow.com/insight/ceo-and-president-chapman-steven-leonard-sold-9089776-worth-of-6592292 https://quantisnow.com/insight/ceo-and-president-chapman-steven-leonard-sold-9089776-worth-of-6592292 Sat, 06 Jun 2026 01:05:05 GMT 3 - AMERICAN VANGUARD CORP (0000005981) (Issuer) https://quantisnow.com/insight/sec-form-3-filed-by-new-insider-mcdougal-rubin-j-6592291 https://quantisnow.com/insight/sec-form-3-filed-by-new-insider-mcdougal-rubin-j-6592291 Sat, 06 Jun 2026 01:01:48 GMT 4 - ACM Research, Inc. (0001680062) (Issuer) https://quantisnow.com/insight/officer-cheav-sotheara-exercised-18750-shares-at-a-strike-of-6592290 https://quantisnow.com/insight/officer-cheav-sotheara-exercised-18750-shares-at-a-strike-of-6592290 Sat, 06 Jun 2026 01:00:24 GMT 4 - AMERICAN VANGUARD CORP (0000005981) (Issuer) https://quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-dipaola-michael-6592289 https://quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-dipaola-michael-6592289 Sat, 06 Jun 2026 01:00:08 GMT 4 - Atlas Lithium Corp (0001540684) (Issuer) https://quantisnow.com/insight/chief-executive-officer-fogassa-marc-returned-237792-worth-of-shares-6592288 https://quantisnow.com/insight/chief-executive-officer-fogassa-marc-returned-237792-worth-of-shares-6592288 Sat, 06 Jun 2026 01:00:02 GMT Watch the Official Gameplay Trailer Showcasing a New Take on Turn-Based Tactics Games; Pre-Orders Now Available for PC, PlayStation 5, Xbox Series X|S Electronic Arts Inc. (NASDAQ:EA) today announced that Star Wars Zero Company™, a single-player turn-based tactics game, developed by Bit Reactor in collaboration with Lucasfilm Games, will be available on PC, PlayStation® 5 and Xbox Series X|S starting August 27, 2026. Pre-Orders are now available on all platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605316929/en/Star Wars Zero Company Key Art A new gameplay trailer delivers an action-packed look at the game's grit https://quantisnow.com/insight/command-the-clone-wars-most-cunning-operatives-in-star-wars-6592287 https://quantisnow.com/insight/command-the-clone-wars-most-cunning-operatives-in-star-wars-6592287 Sat, 06 Jun 2026 01:00:00 GMT 4 - SITIME Corp (0001451809) (Issuer) https://quantisnow.com/insight/chief-executive-officer-vashist-rajesh-sold-28045200-worth-of-shares-6592286 https://quantisnow.com/insight/chief-executive-officer-vashist-rajesh-sold-28045200-worth-of-shares-6592286 Sat, 06 Jun 2026 00:54:58 GMT 4 - AMERICAN VANGUARD CORP (0000005981) (Issuer) https://quantisnow.com/insight/director-gottschalk-patrick-e-was-granted-31872-shares-increasing-direct-6592285 https://quantisnow.com/insight/director-gottschalk-patrick-e-was-granted-31872-shares-increasing-direct-6592285 Sat, 06 Jun 2026 00:54:50 GMT 4 - SITIME Corp (0001451809) (Issuer) https://quantisnow.com/insight/officer-assaderaghi-fariborz-sold-1413694-worth-of-shares-2000-units-6592284 https://quantisnow.com/insight/officer-assaderaghi-fariborz-sold-1413694-worth-of-shares-2000-units-6592284 Sat, 06 Jun 2026 00:54:35 GMT 4 - H2O AMERICA (0000766829) (Issuer) https://quantisnow.com/insight/chief-executive-officer-walters-andrew-f-gifted-3508-shares-decreasing-6592283 https://quantisnow.com/insight/chief-executive-officer-walters-andrew-f-gifted-3508-shares-decreasing-6592283 Sat, 06 Jun 2026 00:51:40 GMT SCHEDULE 13G/A - Hub Cyber Security Ltd. (0001905660) (Subject) https://quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-hub-cyber-security-6592282 https://quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-hub-cyber-security-6592282 Sat, 06 Jun 2026 00:50:40 GMT